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IntroduCtIon
There has been significant effort in linking 
different electronic datasets within health-
care and between health and social care,1–6 
both for research purposes and for clinical 
care. These electronic data are referred to 
as ‘routinely collected’ as they are collected 
during usual clinical practice, in contrast 
to ‘research’ data which are collected in 
a bespoke manner within the context of a 
research project. Such datasets (here referred 
to as routinely collected electronic health 
and social care data) are already used exten-
sively in epidemiological research, to assess 
the impact of healthcare interventions in 
real- world practice, and to provide outcome 
measures in clinical trials.7–9
In wider society, the actions of large 
personal data processors have brought public 
scrutiny on the use and misuse of personal 
data. Previous attempts at large- scale use of 
electronic health and social care data (eg, the 
national Electronic Health Record (EHR) 
in England) have been controversial in 
concept and problematic in execution, with 
consequent damage to public confidence 
in the ability of organisations to act as trust-
worthy stewards of personal data.10–13 These 
negative experiences damage the relation-
ship between individuals, their data and the 
research community.14 We argue for moving 
towards a model of consent and use based on 
respect for digital personhood, and review 
some of the technical and governance solu-
tions that could enable this transition.
differences in data generation and use
Routinely collected electronic health and 
social care data differ from data generated 
by traditional research studies. The primary 
expectation of research participants in the 
traditional research model is that their data 
are collected and used, with consent, for 
research purposes. In contrast, patients and 
service users may not know that routinely 
collected electronic health and social care 
data may be used for research. In a tradi-
tional research study, there is opportunity 
to maintain regular contact and therefore 
foster collaborative, ongoing consent.15 For 
researchers using routinely collected data 
scope for collaborative data use is limited. 
As routinely collected data are not limited to 
a specific research need or time period, the 
volume of information is much greater than 
would typically be collected in a traditional 
research study.
Public attitudes
Most people in the UK are happy to consent 
to use of their routinely collected elec-
tronic health and social care data for ethi-
cally approved research by university and 
National Health Service (NHS) researchers,16 
reflecting the high levels of trust in health-
care professionals and researchers.17 18 Public 
acceptance is lower for commercial research 
data use,19 20 despite the potential added 
value that commercial partners bring to 
improving healthcare.21 This added value is at 
risk if the public are not convinced that their 
data will be used in an ethical way.21 Lack of 
trust in commercial data providers explains 
global trends towards greater regulation—
for instance, the General Data Protection 
Regulation (GDPR)22 in Europe, California’s 
Consumer Privacy Act (California, 2018) and 
even companies such as Facebook now openly 
asking for more government control.23
digital personhood
The way that personal data are considered 
within ethical and legal frameworks has 
undergone an important shift over the last 
few decades. Personal data are often now 
considered part of a person in the same way 
that body parts and tissue samples are part of 
a person.24 This concept of ‘digital person-
hood’ supposes that the data about a person, 
and the transactions on that data, are an 
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integral part of their persona, and that rights pertaining 
to personhood should be extended to incorporate these 
data.25
Ensuring that digital personhood is fully respected 
hinges on how consent is both conceptualised and oper-
ationalised. In a traditional research study, voluntary, 
uncoerced, transparently and honestly acquired consent 
is sought at the onset of the research. Consent requires 
capacity to understand, retain and weigh the relevant 
information. Close interaction with the research team 
affords opportunities to ensure that consent is fully 
informed, opt- in, provides opportunities for participants 
to change their mind, and in many cases allows partici-
pants to personalise the components of the study that they 
consent to. Each further interaction with the research 
team presents an opportunity to reaffirm, modify or with-
draw consent. This ongoing, two- way process of consent 
maximises choice and autonomy for the participant.
Informed, ongoing consent
How can the current processes for research using 
routinely collected health and social care data be adapted 
to ensure that digital personhood is fully respected? We 
propose mechanisms by which the consent relationship 
can be maximised while preserving the ability to conduct 
efficient and generalisable research.
Reciprocal communication
For research using routinely collected electronic health 
and social care data, reciprocal communication can be 
challenging, as the individualised pathway to gain and 
reaffirm consent may not exist at scale in current EHR 
systems. Technology can help however—communica-
tion can be facilitated through ‘patient portal’ applica-
tions, allowing researchers to inform participants about 
research achievements, allow participants to provide 
feedback and allow participants to exercise their rights 
over the use of the data, such as the right to withdraw 
from a particular research use.26 This would resemble 
the traditional researcher–participant relationship more 
closely than the current model.
As with traditional research, upholding the right not to 
participate in research risks losing participants, compro-
mising the validity and generalisability of research. 
Nonetheless, this is a crucial part of developing and main-
taining trust. Attempts to avoid developing these research 
relationships are more likely to lead to a loss of trust in 
the whole research process, with individuals rescinding or 
restricting access potentially in large numbers. Building 
these relationships with individuals may also stimulate 
new opportunities—particularly for individuals to put 
forward and then shape research questions of impor-
tance, facilitating the emergence of genuine codesign 
and coanalysis in research using routinely collected data.
Understandable information
Access to transparent information using plain language 
is essential to support understanding about the potential 
use of routinely collected electronic health and social care 
data in research. Information is currently delivered at 
population level, via advertising campaigns, information 
leaflets and information boxes on clinical appointments. 
Such methods have arguably failed to deliver individual-
ised, tailored information. There is a growing expectation 
that individuals should be able to access their own health 
and social care data, and applications such as the patient 
portal1 can help to deliver such information. Applications 
to manage chronic disease are another example of this 
approach (eg, the My Diabetes My Way application).27
Managing consent
The design of routinely collected data consent systems 
would benefit greatly from public and patient involve-
ment, either through extensive consultation or fully 
participatory codesign. The process of consent should 
incorporate mechanisms that support ease of access for 
individuals to their data. For consent to be meaningful, 
individuals need to have a sense of control over their 
data. They need to be able to request the correction 
or removal of inaccurate or inappropriately held data, 
rights currently embedded in GDPR legislation.22 Mech-
anisms must enable individuals to withdraw or change 
consent. The increasing complexity of health and social 
care records means that it may be technically possible 
for individuals to express a preference as to what parts 
of their data can be accessed by different parties, as is the 
case with the patient portal application being deployed 
as part of the Great North Care Record.1 Legislation 
also requires that preferences are processed in a timely 
manner, are shown to have been executed and that data 
no longer relevant to the original consented purpose 
are removed from linked datasets derived for research 
analysis (including backups). Supporting these processes 
carries costs, both in time and money, and these costs 
need to be acknowledged by researchers and funders.
regulatory frameworks
Governance and regulatory frameworks exist to protect 
the safety and rights of individuals, with most research 
being submitted, reviewed and approved on a project- 
by- project basis, an approach developed for tradi-
tional research involving small numbers of participants 
consenting face to face. Balancing regulation against the 
burden on research teams, funders and institutions is 
challenging.28 29 Research involving routinely collected 
health and social care data typically involves multiple 
uses of the same datasets, often with access by multiple 
research groups. An opportunity exists to move away 
from traditional project- by- project approval to centralised 
or federated data warehouses, platforms and gover-
nance approvals. Governance and regulatory structures 
currently lag behind these technological advances in data 
management and research use. The focus of governance 
should shift to platform level rather than project level—
an approach used successfully by the Dundee Health 
Informatics Centre,2 in which a single umbrella ethics 
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approval covers a wide range of health informatics proj-
ects, with per- project approval devolved to a data access 
committee with external oversight. Other related exam-
ples are of large scale, reusable data repositories of anony-
mised medical data (eg, UK Biobank and the Scottish 
GO- SHARE—Survey of Health, Ageing and Retirement 
in Europe—project30 31). Developing and using such 
platforms also provide an opportunity for in- depth and 
sustained collaboration between research teams and the 
public in the design, governance and delivery of infor-
matics research in a way that may not be possible with 
multiple standalone projects.
Challenges, solutIons and examPles
Using routinely collected healthcare and social data for 
research poses challenges to the consent model used in 
traditional research studies—both of conceptualisation 
and of operationalisation. The current UK legal frame-
work (the GDPR) allows use of such data for research 
without consent under ‘fair use’ provisions. This principle 
attempts to balance wider societal benefits against the 
rights contained in the concept of digital personhood. To 
limit the adverse impact of such use, these provisions stip-
ulate that data must be acquired in a lawful manner, be 
used exclusively for the set purpose, and that the amount 
of data collected, and the length of time for which the 
data are kept, must not exceed what is necessary to achieve 
that purpose. What is lacking is the opportunity for indi-
viduals to give or withhold consent to some or all research 
uses of their data across an extended time period. Even 
where such provision does exist, the processes required 
to enable ongoing consent may be difficult and time 
consuming, as evidenced by the parallel example of oper-
ationalising the ‘right to be forgotten’ provisions within 
GDPR32 highlighted by recent cases.33
An individualised consent model may not be suitable 
for all populations, for example, those who cannot give 
consent, vulnerable groups, those without digital access 
or skills or those who have died. For these reasons, the 
application of such a mechanism to a specific research 
project should be a matter for the ethics committee, 
allowing certain studies to use alternative mechanisms. 
Even in such cases, individualised mechanisms would 
still be valuable as an information or communication 
channel between researchers and participants. In addi-
tion, specific mechanisms to support those who are less 
digitally literate in exercising their consent choices need 
to be built into platforms and governance systems.
There is an inherent tension between individual rights 
and the public good; the concern with moving to a system 
of individualised consent for use of routinely collected 
data is that such a system would impair the ability of 
researchers to deliver generalisable research as a public 
good. It has recently been argued34 that the current model 
is not only sufficient, but that the ethical locus of control 
for such studies is appropriately sited within authority 
or governance structures rather than at the level of an 
individual contributing data—and that moving away from 
this current model is not practical. The practical issues 
can now be addressed using technological solutions, and 
the ethical arguments in favour of the current system are 
irrelevant if the public does not concur. A model giving 
choice to individuals needs to encompass changes of pref-
erence over time needs to include feedback on how data 
are used and to what benefit, thus building the ongoing 
relationship between researchers and participants.35 
Failure to do so could threaten the trust required for 
clinical care, and in the long term would render such 
data useless for research if a significant proportion of 
the population withheld their data. Although there are 
concerns that withdrawal of consent by individuals might 
jeopardise historical data or data already published, these 
issues are already managed within traditional research 
governance structures which give clear the limitations on 
how existing analyses will be amended. Initiatives such as 
the Wellcome Trust ‘Understanding Patient Data’36 are 
essential to raising public awareness and engagement on 
how data are used without explicit consent for healthcare 
research and build widespread public buy- in; nonethe-
less such initiatives should not detract from developing 
models of explicit consent for such work.
Appropriate technical infrastructure is an integral part 
of any solution to enabling widespread use of routinely 
collected health and social care data. Trusted Research 
Environments (‘Safe Havens’ or ‘Walled Gardens’) are 
a popular model enabling research use of routinely 
collected data in a secure and controlled way.2–5 They are 
usually implemented as a virtual environment, or for very 
sensitive data, using a terminal located in a controlled 
physical environment. They allow control of access, 
control what analytical tools can be used and importantly 
control what data can enter or leave the environment (ie, 
no identifiable data; aggregate results only)—including 
statistical disclosure control (ie, individuals cannot be 
identified retrospectively from aggregate outputs if there 
are rare conditions or small populations). These envi-
ronments are now being incorporated into electronic 
healthcare records via projects such as Connected Health 
Cities.3 Such environments also enable individuals to 
withdraw consent for use of their routinely collected 
healthcare and social data without a risk of identification 
by researchers.
Centralising the technology and governance frame-
works requires strategic investment. Health services 
have already recognised this need; NHS England has 
commenced the Global Digital Exemplar initiative,37 
and examples such as the Great North Care Record are 
creating a regional single point of access for health data.1 
While primarily enabling more joined- up health and 
social care, these platforms are also well suited for use by 
researchers. Research organisations such as the National 
Institute for Health Research Biomedical Research 
Centres and the Health Data Research UK Digital Innova-
tion Hubs are well placed to oversee and enable this work. 
Embedding these research environments within clinical 
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records also provide the necessary universal coverage for 
population- level research in a way that separate opt- in 
schemes (eg, GO- SHARE)31 may not achieve.
ConClusIon
The research value of routinely collected electronic health 
and social care data depends on maintaining high levels 
of public trust in how researchers use such data. Crucial 
to maintaining trust is ensuring that digital personhood 
is respected: robust, ongoing consent processes must 
be developed to facilitate this. Challenges in how such 
consent processes are operationalised can be overcome 
by adopting appropriate organisational, technical and 
governance structures. Changing public expectations 
around data use and digital personhood mandate that 
researchers, funders and health and social organisations 
implement solutions to support ongoing, flexible and 
accessible consent processes for routinely collected data 
research. The alternative—a loss of trust and a conse-
quent loss of this valuable research ability—would harm 
all of us who use health and social care services.
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